The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway

DR5 Receptor Mediates Anoikis in Human Colorectal Carcinoma Cell Lines

(2008) L. M. Laguinge et al.   CANCER RESEARCH

TRAIL Inactivates the Mitotic Checkpoint and Potentiates Death Induced by Microtubule-Targeting Agents in Human Cancer Cells

(2008) M. Kim et al.   CANCER RESEARCH

Mcl-1: A Gateway to TRAIL Sensitization

(2008) S.-H. Kim et al.   CANCER RESEARCH

Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5

(2008) C Adams et al.   CELL DEATH AND DIFFERENTIATION

A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies

(2008) S. J. Hotte et al.   CLINICAL CANCER RESEARCH

TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development

(2008) Anne Grosse-Wilde et al.   JOURNAL OF CLINICAL INVESTIGATION

To kill a tumor cell: the potential of proapoptotic receptor agonists

(2008) Avi Ashkenazi et al.   JOURNAL OF CLINICAL INVESTIGATION

TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis

(2008) Niklas Finnberg et al.   JOURNAL OF CLINICAL INVESTIGATION